Takeda Pharmaceutical Company Limited Total Liabilities
Takeda Pharmaceutical Company Limited total liabilities. Based on the latest financial reports, Takeda Pharmaceutical Company Limited (TKDA) has total liabilities worth €7.76 Trillion EUR (≈ $9.08 Trillion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See TKDA defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Takeda Pharmaceutical Company Limited (2017–2025)
Total liabilities of Takeda Pharmaceutical Company Limited from 2017 to 2025. This chart illustrates how Takeda Pharmaceutical Company Limited's total liabilities have evolved over time, based on quarterly financial data. Check TKDA asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Takeda Pharmaceutical Company Limited Competitors by Total Liabilities
The table below lists competitors of Takeda Pharmaceutical Company Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥8.30 Billion |
|
Agilent Technologies Inc
NYSE:A
|
USA | $5.99 Billion |
|
Coca-Cola European Partners PLC
NASDAQ:CCEP
|
USA | $23.28 Billion |
|
Haleon plc
NYSE:HLN
|
USA | $16.04 Billion |
|
STANDARD CHART.UNSP.ADR/2
F:STD0
|
Germany | €918.22 Billion |
|
Danske Bank A/S
CO:DANSKE
|
Denmark | Dkr3.62 Trillion |
|
Siemens Healthineers AG
F:SHL
|
Germany | €26.58 Billion |
|
Cardinal Health Inc
NYSE:CAH
|
USA | $59.36 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Takeda Pharmaceutical Company Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Takeda Pharmaceutical Company Limited balance sheet assets.
Liquidity & Leverage Metrics
Takeda Pharmaceutical Company Limited Total Liabilities Ratios Explained
Takeda Pharmaceutical Company Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Takeda Pharmaceutical Company Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Takeda Pharmaceutical Company Limited (2017–2025)
The table below shows the annual total liabilities of Takeda Pharmaceutical Company Limited from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | €7.31 Trillion ≈ $8.55 Trillion |
-6.67% |
| 2024-03-31 | €7.83 Trillion ≈ $9.16 Trillion |
+3.05% |
| 2023-03-31 | €7.60 Trillion ≈ $8.89 Trillion |
+1.45% |
| 2022-03-31 | €7.49 Trillion ≈ $8.76 Trillion |
-3.11% |
| 2021-03-31 | €7.74 Trillion ≈ $9.04 Trillion |
-4.43% |
| 2020-03-31 | €8.09 Trillion ≈ $9.46 Trillion |
-7.06% |
| 2019-03-31 | €8.71 Trillion ≈ $10.18 Trillion |
+316.87% |
| 2018-03-31 | €2.09 Trillion ≈ $2.44 Trillion |
-13.20% |
| 2017-03-31 | €2.41 Trillion ≈ $2.81 Trillion |
-- |
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Take… Read more